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Purpose or Objective: Neoadjuvant chemoradiation(nCRT) 
has been represented as the standard treatment for locally 
advanced rectal cancer(LARC). Tumor pathological responses 
and radiotherapeutic sensitivity alter variously. We aimed to 
explore the predict value of serum circulating miRNAs, which 
have already been certificated as potential therapeutic 
predictors in many cancers for the pathological responses and 
radiosensitivity after nCRT in LARC patients. 
 
Material and Methods: Six fresh tumor biopsy samples of T3-
4/N+ rectal cancer patients were collected before any 
treatments and these samples were classified as radiation 
sensitive and resistant groups according to the postoperative 
pathological analysis assessed by Mandard TRG scale(3 
samples of TRG1 vs 3 samples of TRG4). The two groups were 
strictly matched by clinical features. miRNAs expression 
profile of the two groups were analyzed by microarray. 
Predictive value of radiotherapeutic sensitivity of the 
candidated miRNAs was further validated by 160 serum 
samples of LARC patients.  
 
Results: 19 miRNAs were identified to have different 
expression profile between radiation sensitive and resistant 
groups by microarray analysis (p<0.05). Among these miRNAs, 
nine miRNAs were down-regulated and ten were up-regulated 
in radiation sensitive group. miR-345-5p was identified 
significantly correlated with radiation resistant to nCRT and 
appeared highly discrepant expression between the two 
groups (fold change>2). Low expression of miR-345-5p in 
serum predicted superior pathological responses to 
radiosensitivity after nCRT (TRG1/2) (AUC=0.69, p<0.001) and 




Conclusion: Serum level of miR-345-5p is associated with 
favorable pathological responses to neoadjuvant 
chemoradiotherapy and local-regional control ratio in LARC 
patients. It presents as a promising biomarker to predict the 
radiotherapy sensitivity and prognosis. 
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Purpose or Objective: To evaluate the significance of 
postoperative carcinoembryonic antigen (CEA) level as a 
predictor for tumor recurrence and as a prognostic factor for 
survival in locally advanced rectal cancer patients treated 
with preoperative concurrent chemoradiation followed by 
curative surgery 
 
Material and Methods: Total 1559 rectal cancer patients 
staged with cT3-4N0-2M0 received pelvic preoperative 
chemoradiotherapy (CRT) 50.4 Gy in 28 fractions followed by 
total mesorectal excision (TME). CEA levels were measured 
before CRT and after surgery. Clinicopathologic factors which 
could be associated with tumor recurrence and survival were 
analyzed. 
 
Results: The cumulative probability of the tumor recurrence 
showed a steep increase with a cutoff value of 2.5 ng/mL for 
postoperative CEA, and the gradient decreased as 
postoperative CEA levels increased above 2.5 ng/mL. After 
median follow-up time of 46.7 months, patients with 
postoperative CEA level of > 2.5 ng/mL had significantly 
lower relapse-free survival (75.6% vs. 65.2%, p<0.001) and 
overall survival (88.3% vs. 78.1%, p<0.001) at 5 years than 
patients with CEA level of ≤2.5 ng/mL. In the multivariate 
analysis, postoperative CEA level is the only significant 
prognostic factors of relapse free survival (HR=1.561 and 95% 
CI=1.221-1.996, p<0.001) and overall survival (HR=2.073 and 
95% CI=1.498-2.869, p<0.001). Increased pre-CRT CEA level is 
not a significant prognostic factor with consideration of 
postoperative CEA in multivariate analysis. The postoperative 
CEA level above 2.5 ng/ml is a significant predictor for 
distant recurrence (OR=1.689 and 95% CI=1.188-2.402, 
p=0.004), but not for local recurrence (OR=0.776 and 95% 
CI=0.389-1.549, p=0.472). 
 
Conclusion: Postoperative CEA level above 2.5 ng/ml is a 
predictor for tumor recurrence and a negative prognostic 
factor for survival in rectal cancer patients who received 
preoperative CRT and curative surgery. Physician can 
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